

**Supporting Table 1: Cohort 3 Post-Induction Therapy and Disease Response**

Therapy Sequence	Pt (n)	Number of Treatment Cycles (number of patients)	End-Induction Overall INRC Response <sup>1</sup>	Post-Induction Overall INRC Response <sup>1</sup>	Event Y/N	Death Y/N
DIT, MIBG	1	DIT: 2 MIBG: 1	MR: 1	MR: 1	1/0	1/0
I/T, MIBG, NANT 2009-03 (I/T/alisertib), pembro, DIT, radiation, dinutuximab, radiation, surgery	1	I/T: 2 MIBG: 1 I/T/alisertib: 4 Pembro: 28 DIT: 4 Dinutuximab: Unknown	SD: 1	PR: 1	1/0	0/1
DIT, surgical resection, MIBG, NANT2013-01 (Dinituximab with NK cells), RA	1	DIT: 4 Dinutuximab and NK cells: 4 RA: unknown	MR: 1	MR: 1	0/1	0/1
MIBG, DIT, and radiation	1	MIBG: 1 DIT: 14	PR: 1	PR: 1	1/0	0/1
MIBG, HU 3F8 antibody with GM-CSF, bivalent vaccine and oral beta glucan	1	MIBG: 2 HU 3F3: unknown	MR: 1	PR: 1	0/1	0/1
I/T, MIBG, NANT 2009-03 (alisertib and I/T), ADVL1213 (ontuxizumab; MORAb-004)	1	I/T: 3 MLN8237 I/T: 2 Ontuxizumab: 3	PR: 1	PR: 1	1/0	0/1
MIBG, Crizotinib	1	MIBG: 2 Crizotinib: 2	MR: 1	MR: 1	1/0	0/1
MIBG, Crizotinib, DIT	1	MIBG: Crizotinib: 3 DIT: 2	PR: 1	MR: 1	1/0	1/0
I/T, MIBG	1	I/T: 2 MIBG: 2	MR: 1	MR: 1	1/0	1/0
Cyclo/Topo, MIBG, ADVL0918 (I/T, temsirolimus), Cyclo/Topo	1	Cyclo/Topo: 1 MIBG: 1 Cyclo/Topo: 6	MR: 1	CR: 1	0/1	0/1
DIT	3	1 (n=1) 3 (n=1) 8 (n=1)	PR: 1 MR: 2	PR: 1 PD: 2	3/0	3/0

**Supporting Table 1: continued**

Therapy Sequence	Pt (n)	Number of Treatment Cycles (number of patients)	End-Induction Overall INRC Response <sup>1</sup>	Post-Induction Overall INRC Response <sup>1</sup>	Event Y/N	Death Y/N
DIT, radiation, DIT, HU 3F8, DFMO	1	DIT: 5 DIT: 4 HU 3F8: 1 DFMO: Unknown	MR: 1	CR: 1	0/1	0/1
DIT, DFMO	1	DIT: 4 DFMO: Unknown	PR: 1	CR: 1	0/1	0/1
DIT, Radiation	2	DIT: 3 (n=1) 17 (n=1)	PR: 1 SD: 1	CR: 1 PD: 1	1/1	1/1
DIT, RA	1	DIT: 8 RA: 1	PR: 1	PR: 1	0/1	0/1
DIT, cerlitinib	1	DIT: 8 Cerlitinib: 2	MR: 1	PR: 1	0/1	0/1
Crizotinib, zometa/cyclo, cyclo/topo, crizotinib	1	Crizotinib: 26 Zometa/cyclo: 2 Cyclo/Topo: 8 Crizotinib: 1	MR: 1	PR: 1	1/0	1/0
Cyclo/Topo	1	2	PR: 1	PD: 1	1/0	0/1
ADVL1213 (ontuxizumab (MORAb-004), nifurtimox, I/T, RA, CAR-T/pembro	1	ADVL1213 : Unknown Nifurtimox: 3 I/T: 2 RA: 2	PR: 1	PR: 1	1/0	0/1
Irinotecan and bortezomib	1	Unknown	SD:1	PD: 1	1/0	0/1
I/T	2	13 (n=1) 2 (n=1)	MR: 1 SD: 1	PD: 2	2/0	2/0
Radiation only	1	NA	PR: 1	PR: 1	1/0	1/0
HU 3F8, radiation	1	HU 3F8: 5	PR: 1	PD:1	1/0	0/1

Abbreviations: CAR-T, chimeric antigen receptor T cell; CR, complete response; Cyclo/Topo, cylophosphamide and topotecan; DFMO, difluoromethylornithine; DIT, dinutuximab, GD2, disialoganglioside antigen; HU 3F8, humanized 3F8; irinotecan, and temodar; I/T, irinotecan, and temodar; MIBG, meta-iodobenzylguanidine; MR, minimal response; n, number; NK, natural killer; pembro, pembrolizumab; PD, progressive disease; PR, partial response; RA, retinoic acid; SD, stable disease

**Supporting Table 1: continued**

<sup>1</sup>Overall response was determined using two components if bone marrow was not done